[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

C4 Therapeutics Inc (CCCC)

C4 Therapeutics Inc (CCCC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 427,894
  • Shares Outstanding, K 110,567
  • Annual Sales, $ 35,950 K
  • Annual Income, $ -104,990 K
  • EBIT $ -103 M
  • EBITDA $ -104 M
  • 60-Month Beta 2.91
  • Price/Sales 11.13
  • Price/Cash Flow N/A
  • Price/Book 1.70

Options Overview Details

View History
  • Implied Volatility 85.75% (-31.14%)
  • Historical Volatility 61.91%
  • IV Percentile 1%
  • IV Rank 0.74%
  • IV High 484.59% on 02/17/26
  • IV Low 82.78% on 05/05/26
  • Expected Move (DTE 9) 0.43 (10.90%)
  • Put/Call Vol Ratio 0.76
  • Today's Volume 253
  • Volume Avg (30-Day) 930
  • Put/Call OI Ratio 0.06
  • Today's Open Interest 26,978
  • Open Int (30-Day) 25,044
  • Expected Range 3.48 to 4.33

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $-0.21
  • Number of Estimates 1
  • High Estimate $-0.21
  • Low Estimate $-0.21
  • Prior Year $-0.44
  • Growth Rate Est. (year over year) +52.27%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.36 +16.07%
on 08/03/26
4.05 -3.70%
on 07/13/26
-0.16 (-3.94%)
since 07/10/26
3-Month
3.05 +27.87%
on 05/19/26
5.17 -24.56%
on 06/30/26
+0.73 (+23.03%)
since 05/12/26
52-Week
1.69 +130.76%
on 02/05/26
5.17 -24.56%
on 06/30/26
+1.66 (+74.11%)
since 08/12/25

Most Recent Stories

More News
C4 Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Cemsidomide’s Ongoing Phase 2 MOMENTUM Trial and Phase 1b Trial in Combination With Elranatamab Remain on Track to Deliver Clinical Data Readouts in 2027 Phase 1 Data Presented at European Hematology...

CCCC : 3.90 (+0.78%)
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

WATERTOWN, Mass., Aug. 10, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science,...

CCCC : 3.90 (+0.78%)
C4 Therapeutics Reports Tomorrow With Shrinking Revenue Forecasts Already Priced In—Or Not

Barchart Research What to Expect from CCCC Earnings CCCC Generated August 5, 2026 Current Price $3.62 EPS Estimate $$-0.23 Consensus Rating Strong Buy Average Move 5.58% C4 Therapeutics Reports Tomorrow...

CCCC : 3.90 (+0.78%)
C4 Therapeutics Presents Phase 1 Data at European Hematology Association (EHA) 2026 Congress Highlighting Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader for Multiple Myeloma in Heavily Pretreated Relapsed/Refractory Population

At the 100 µg Recommended Phase 2 Dose (RP2D), Cemsidomide Demonstrated a 53% Overall Response Rate, Including Complete Responses and Minimal Residual Disease (MRD) Negative Status  Cemsidomide...

CCCC : 3.90 (+0.78%)
C4 Therapeutics to Participate in Upcoming Conferences

WATERTOWN, Mass., May 20, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation (TPD) science,...

CCCC : 3.90 (+0.78%)
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

WATERTOWN, Mass., May 18, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science,...

CCCC : 3.90 (+0.78%)
C4 Therapeutics Reports Tuesday: The Revenue Volatility Question Returns

Barchart Research What to Expect from CCCC Earnings CCCC Generated May 12, 2026 Current Price $3.17 EPS Estimate $$-0.21 Consensus Rating Strong Buy Average Move 6.20% C4 Therapeutics Reports Tuesday:...

CCCC : 3.90 (+0.78%)
C4 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights

Progressed Plans to Establish Cemsidomide as a Potentially Foundational Treatment for Multiple Myeloma; Enrollment Ongoing in Phase 2 MOMENTUM Trial and Phase 1b Trial in Combination with Elranatamab ...

CCCC : 3.90 (+0.78%)
C4 Therapeutics Expands Long-Term Partnership with Roche Through New Collaboration Agreement Focused on Discovering and Developing Degrader-Antibody Conjugates (DACs)

Agreement Focused on Developing DACs With Payloads For Two Oncology Targets, With an Option for a Third Target C4T to Develop Degraders With Payload Properties; Roche to Conjugate Payloads to Targeted...

RHHBY : 56.5100 (-0.19%)
CCCC : 3.90 (+0.78%)
C4 Therapeutics Announces First Patient Dosed in Phase 1b Trial of Cemsidomide in Combination with Elranatamab (ELREXFIO®) for Relapsed/Refractory Multiple Myeloma

WATERTOWN, Mass., March 25, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science,...

CCCC : 3.90 (+0.78%)

Business Summary

C4 Therapeutics Inc. is a biopharmaceutical company. It is focused on harnessing the body's natural regulation of protein levels to develop novel therapeutic candidates to target and destroy disease-causing proteins for the treatment of cancer, neurodegenerative conditions and other diseases. C4 Therapeutics...

See More

Key Turning Points

3rd Resistance Point 4.39
2nd Resistance Point 4.20
1st Resistance Point 4.03
Last Price 3.90
1st Support Level 3.67
2nd Support Level 3.48
3rd Support Level 3.31

See More

52-Week High 5.17
Last Price 3.90
Fibonacci 61.8% 3.84
Fibonacci 50% 3.43
Fibonacci 38.2% 3.02
52-Week Low 1.69

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.